Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

Rivian Automotive (RIVN) trades at $12.95, down 4.36% amid a bearish technical signal despite beating Q3 2026 delivery estimates with 19,248 vehicles. The company maintains negative profitability with a net income margin of -54.95% but shows improving revenue trends, reaching $5.39 billion in 2025. Cash flow remains negative, though operational losses have narrowed significantly from previous years.

The stock presents a high-risk opportunity with Wall Street consensus leaning bullish (48% buy ratings) and a $16.89 price target, implying potential upside. Key risks include persistent cash burn, intense EV competition, and execution challenges in scaling R2 production and autonomy technology, which are critical for achieving profitability.